Analysts expect Evogene Ltd (NYSE:EVGN) to report earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evogene’s earnings. Evogene reported earnings of ($0.18) per share in the same quarter last year, which indicates a positive year over year growth rate of 5.6%. The firm is scheduled to report its next earnings report on Thursday, August 10th.
According to Zacks, analysts expect that Evogene will report full year earnings of ($0.51) per share for the current year. For the next financial year, analysts anticipate that the company will post earnings of ($0.02) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Evogene.
Evogene (NYSE:EVGN) last issued its quarterly earnings results on Wednesday, May 17th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%. The business had revenue of $0.72 million during the quarter.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG increased its stake in Evogene by 10.2% in the third quarter. UBS Group AG now owns 822,331 shares of the biotechnology company’s stock worth $5,246,000 after buying an additional 76,323 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock worth $4,079,000 after buying an additional 85,425 shares during the last quarter. Vanguard Group Inc. increased its stake in Evogene by 4.2% in the first quarter. Vanguard Group Inc. now owns 418,834 shares of the biotechnology company’s stock worth $2,240,000 after buying an additional 16,964 shares during the last quarter. Bank of America Corp DE increased its stake in Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock worth $4,500,000 after buying an additional 42,532 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Evogene by 71.1% in the first quarter. Jane Street Group LLC now owns 50,129 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 20,837 shares in the last quarter. 29.88% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Evogene (NYSE:EVGN) traded down 3.6180% during trading on Thursday, reaching $5.0215. 1,030 shares of the company traded hands. The company’s market capitalization is $128.68 million. Evogene has a 1-year low of $4.86 and a 1-year high of $7.09. The stock’s 50 day moving average is $5.21 and its 200 day moving average is $5.28.
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.